Skip to main content
Journal of Hematology & Oncology logoLink to Journal of Hematology & Oncology
. 2023 Feb 20;16:13. doi: 10.1186/s13045-023-01414-8

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Qian Jiang 1, Zongru Li 1, Yazhen Qin 1, Weiming Li 2, Na Xu 3, Bingcheng Liu 4, Yanli Zhang 5, Li Meng 6, Huanling Zhu 7, Xin Du 8, Suning Chen 9, Yang Liang 10, Yu Hu 2, Xiaoli Liu 3, Yongping Song 5, Lichuang Men 11, Zi Chen 11, Qian Niu 11, Hengbang Wang 11, Ming Lu 12, Dajun Yang 13,14, Yifan Zhai 11,12, Xiaojun Huang 1,15,16,17,
PMCID: PMC9942283  PMID: 36803531

Correction to: Journal of Hematology & Oncology (2022) 15:159 10.1186/s13045-022-01369-2

The original article [1] presented an incorrect biochemical structure of olverembatinib in Supplementary Figure 1; in addition, the correct structure had indeed already been published.

The figure has since been removed.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Jiang Q, Li Z, Qin Y, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15:159. doi: 10.1186/s13045-022-01369-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Hematology & Oncology are provided here courtesy of BMC

RESOURCES